Coldstream Capital Management Inc. reduced its stake in Bristol-Myers Squibb Co. (NYSE:BMY) by 4.1% during the second quarter, according to its most recent filing with the SEC. The firm owned 12,051 shares of the biopharmaceutical company’s stock after selling 509 shares during the period. Coldstream Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $886,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of BMY. Fisher Asset Management LLC boosted its position in Bristol-Myers Squibb by 371.9% in the first quarter. Fisher Asset Management LLC now owns 636,060 shares of the biopharmaceutical company’s stock valued at $43,284,000 after buying an additional 501,260 shares during the period. Davis R M Inc. raised its stake in shares of Bristol-Myers Squibb by 1.2% in the first quarter. Davis R M Inc. now owns 21,420 shares of the biopharmaceutical company’s stock valued at $1,368,000 after buying an additional 259 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Bristol-Myers Squibb during the first quarter valued at about $364,000. Sigma Planning Corp raised its stake in shares of Bristol-Myers Squibb by 4.4% in the first quarter. Sigma Planning Corp now owns 23,659 shares of the biopharmaceutical company’s stock valued at $1,511,000 after buying an additional 997 shares in the last quarter. Finally, Private Trust Co. NA raised its stake in shares of Bristol-Myers Squibb by 3.3% in the first quarter. Private Trust Co. NA now owns 66,821 shares of the biopharmaceutical company’s stock valued at $4,268,000 after buying an additional 2,147 shares in the last quarter. Institutional investors own 72.91% of the company’s stock.
Bristol-Myers Squibb Co. (NYSE:BMY) traded up 1.79% on Tuesday, hitting $55.64. The stock had a trading volume of 4,650,104 shares. The company’s 50 day moving average is $56.87 and its 200-day moving average is $67.07. Bristol-Myers Squibb Co. has a 12 month low of $53.56 and a 12 month high of $77.12. The stock has a market cap of $92.97 billion, a P/E ratio of 32.54 and a beta of 0.75.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.03. The firm earned $4.90 billion during the quarter, compared to analyst estimates of $4.60 billion. Bristol-Myers Squibb had a return on equity of 24.92% and a net margin of 16.63%. The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.53 EPS. Analysts forecast that Bristol-Myers Squibb Co. will post $2.62 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, November 1st. Investors of record on Friday, October 7th will be given a dividend of $0.38 per share. This represents a $1.52 annualized dividend and a yield of 2.78%. The ex-dividend date is Wednesday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 87.36%.
Several brokerages have issued reports on BMY. Vetr raised Bristol-Myers Squibb from a “sell” rating to a “buy” rating and set a $78.73 target price for the company in a research note on Monday, July 25th. Deutsche Bank AG reissued a “hold” rating on shares of Bristol-Myers Squibb in a research note on Wednesday, June 15th. BMO Capital Markets reissued a “market perform” rating and set a $60.00 price objective on shares of Bristol-Myers Squibb in a research note on Saturday, September 3rd. Zacks Investment Research downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, July 11th. Finally, SunTrust Banks Inc. downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their target price for the company from $86.00 to $68.00 in a report on Friday, August 5th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $69.91.
In related news, Director Lamberto Andreotti sold 21,600 shares of the company’s stock in a transaction dated Thursday, September 8th. The stock was sold at an average price of $56.87, for a total transaction of $1,228,392.00. Following the transaction, the director now directly owns 334,499 shares of the company’s stock, valued at approximately $19,022,958.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.24% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.